Patents by Inventor John R. Desjarlais

John R. Desjarlais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fc variants with altered binding to FcRn
    Patent number: 11198739
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 14, 2021
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
  • TARGETED IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20210355185
    Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 18, 2021
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat, Eric Chang
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210277095
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: October 23, 2020
    Publication date: September 9, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20210115118
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: March 25, 2020
    Publication date: April 22, 2021
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009690
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20210009689
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20200332024
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 22, 2020
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • OPTIMIZED ANTIBODIES THAT TARGET CD19
    Publication number: 20200317804
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Applicant: XENCOR, INC.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20200262899
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 27, 2020
    Publication date: August 20, 2020
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20200255502
    Abstract: The present application relates toa variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: June 12, 2019
    Publication date: August 13, 2020
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Heterodimeric proteins
    Patent number: 10738132
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
    Publication number: 20200247862
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Application
    Filed: December 20, 2019
    Publication date: August 6, 2020
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20200216509
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Application
    Filed: October 3, 2019
    Publication date: July 9, 2020
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF
    Publication number: 20200140512
    Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
    Type: Application
    Filed: October 11, 2019
    Publication date: May 7, 2020
    Inventors: Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid
  • Optimized antibodies that target CD19
    Patent number: 10626182
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 21, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20200071402
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20190330342
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20190315861
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: May 21, 2019
    Publication date: October 17, 2019
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with altered binding to FcRn
    Patent number: 10336818
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 2, 2019
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20180215821
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 2, 2018
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar